Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
The regulation of resistance to IDH inhibitors in acute myeloid leukaemia is not completely understood. Here the authors reveal with integrative multi-omics analyses that stemness features are major drivers of primary resistance, while high-risk mutations drive acquired resistance.
Main Authors: | Feng Wang, Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan, Keyur P. Patel, Kyle J. MacBeth, Bin Wu, Guowen Liu, Mark Frattini, Jairo A. Matthews, Latasha D. Little, Curtis Gumbs, Xingzhi Song, Jianhua Zhang, Erika J. Thompson, Tapan M. Kadia, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Kapil N. Bhalla, Marina Konopleva, Hagop M. Kantarjian, P. Andrew Futreal, Koichi Takahashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-22874-x |
Similar Items
-
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01) -
Acute myeloid leukemia: current progress and future directions
by: Hagop Kantarjian, et al.
Published: (2021-02-01) -
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia
by: Maliha Khan, et al.
Published: (2017-07-01) -
Acute promyelocytic leukemia current treatment algorithms
by: Musa Yilmaz, et al.
Published: (2021-06-01) -
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
by: Alessandro Isidori, et al.
Published: (2021-05-01)